Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy REGENXBIO stock | 35.78

Own REGENXBIO stock in just a few minutes.


Fact checked

REGENXBIO Inc is a biotechnology business based in the US. REGENXBIO shares (RGNX) are listed on the NASDAQ and all prices are listed in US Dollars. REGENXBIO employs 257 staff and has a trailing 12-month revenue of around USD$60.7 million.

How to buy shares in REGENXBIO

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for REGENXBIO. Find the stock by name or ticker symbol: RGNX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until REGENXBIO reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$35.78, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of REGENXBIO, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of REGENXBIO. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted REGENXBIO's share price?

Since the stock market crash in March caused by coronavirus, REGENXBIO's share price has had significant negative movement.

Its last market close was USD$35.78, which is 32.09% down on its pre-crash value of USD$52.69 and 78.63% up on the lowest point reached during the March crash when the shares fell as low as USD$20.03.

If you had bought USD$1,000 worth of REGENXBIO shares at the start of February 2020, those shares would have been worth USD$612.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$786.44.

REGENXBIO share price

Use our graph to track the performance of RGNX stocks over time.

REGENXBIO shares at a glance

Information last updated 2020-10-20.
Latest market close USD$35.78
52-week range USD$20.03 - USD$54.97
50-day moving average USD$28.4551
200-day moving average USD$34.3757
Wall St. target price USD$61
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.359

Buy REGENXBIO shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy REGENXBIO stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

REGENXBIO price performance over time

Historical closes compared with the close of $35.78 from 2020-11-16

1 week (2020-11-13) 3.62%
1 month (2020-10-22) 25.54%
3 months (2020-08-21) 22.70%
6 months (2020-05-22) -17.63%
1 year (2019-11-22) -6.70%
2 years (2018-11-21) -42.23%
3 years (2017-11-22) 20.47%
5 years (2015-11-20) 55.50%

Is REGENXBIO under- or over-valued?

Valuing REGENXBIO stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of REGENXBIO's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.


REGENXBIO's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.26. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into REGENXBIO's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

REGENXBIO financials

Revenue TTM USD$60.7 million
Gross profit TTM USD$-97,193,000
Return on assets TTM -19.89%
Return on equity TTM -30.22%
Profit margin -222.24%
Book value $10.669
Market capitalisation USD$1 billion

TTM: trailing 12 months

Shorting REGENXBIO shares

There are currently 4.3 million REGENXBIO shares held short by investors – that's known as REGENXBIO's "short interest". This figure is 5% down from 4.6 million last month.

There are a few different ways that this level of interest in shorting REGENXBIO shares can be evaluated.

REGENXBIO's "short interest ratio" (SIR)

REGENXBIO's "short interest ratio" (SIR) is the quantity of REGENXBIO shares currently shorted divided by the average quantity of REGENXBIO shares traded daily (recently around 398841.04683196). REGENXBIO's SIR currently stands at 10.89. In other words for every 100,000 REGENXBIO shares traded daily on the market, roughly 10890 shares are currently held short.

However REGENXBIO's short interest can also be evaluated against the total number of REGENXBIO shares, or, against the total number of tradable REGENXBIO shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case REGENXBIO's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 REGENXBIO shares in existence, roughly 120 shares are currently held short) or 0.1845% of the tradable shares (for every 100,000 tradable REGENXBIO shares, roughly 185 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against REGENXBIO.

Find out more about how you can short REGENXBIO stock.

REGENXBIO share dividends

We're not expecting REGENXBIO to pay a dividend over the next 12 months.

REGENXBIO share price volatility

Over the last 12 months, REGENXBIO's shares have ranged in value from as little as $20.03 up to $54.97. A popular way to gauge a stock's volatility is its "beta".

RGNX.US volatility(beta: 0.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while REGENXBIO's is 0.936. This would suggest that REGENXBIO's shares are less volatile than average (for this exchange).

REGENXBIO overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site